ForgIng New Paths to Prevent DIabeTes (FINDIT)
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Endocrine, Diabetes |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 18 - 75 |
| Updated: | 2/10/2019 |
| Start Date: | December 2, 2015 |
| End Date: | March 30, 2020 |
Improving Veteran Engagement in Diabetes Prevention (CDA 13-267-1)
This study will evaluate the effects of screening for type 2 diabetes mellitus (T2DM) and
brief counseling about screening test results on weight and key health behaviors among
Veterans with risk factors for T2DM. Study participants will be randomly assigned to one of
two study groups: (1) Blood Test Group or (2) Brochure Group. Participants in the Blood Test
Group will complete a blood test called hemoglobin A1c (HbA1c) which measures average blood
sugar levels. Participants will receive brief counseling about the results from their primary
care provider or someone authorized to speak on their behalf. Participants randomly selected
for the Brochure Group will review a handout from the VA National Center for Health Promotion
and Disease Prevention (NCP) on recommended screening tests and immunizations. All
participants will be asked to complete a survey prior to study group assignment, immediately
after a Primary Care appointment, 3 months after enrollment, and 12 months after enrollment.
brief counseling about screening test results on weight and key health behaviors among
Veterans with risk factors for T2DM. Study participants will be randomly assigned to one of
two study groups: (1) Blood Test Group or (2) Brochure Group. Participants in the Blood Test
Group will complete a blood test called hemoglobin A1c (HbA1c) which measures average blood
sugar levels. Participants will receive brief counseling about the results from their primary
care provider or someone authorized to speak on their behalf. Participants randomly selected
for the Brochure Group will review a handout from the VA National Center for Health Promotion
and Disease Prevention (NCP) on recommended screening tests and immunizations. All
participants will be asked to complete a survey prior to study group assignment, immediately
after a Primary Care appointment, 3 months after enrollment, and 12 months after enrollment.
An essential step in designing effective strategies to improve patient engagement in behavior
change is to better understand their current levels of engagement in these behaviors and
determine which factors most influence their engagement. Within and outside the Veterans
Health Administration (VHA), little is known about how patients with risk factors for T2DM
view their risk of developing T2DM, what these patients understand about strategies to reduce
this risk, and to what degree at-risk patients are currently engaging in behaviors to prevent
T2DM. This project will generate important new data in these areas and will improve the
investigators' understanding of the effects of a prediabetes diagnosis and brief counseling
on engagement in behaviors to prevent T2DM and mediators of these behaviors.
change is to better understand their current levels of engagement in these behaviors and
determine which factors most influence their engagement. Within and outside the Veterans
Health Administration (VHA), little is known about how patients with risk factors for T2DM
view their risk of developing T2DM, what these patients understand about strategies to reduce
this risk, and to what degree at-risk patients are currently engaging in behaviors to prevent
T2DM. This project will generate important new data in these areas and will improve the
investigators' understanding of the effects of a prediabetes diagnosis and brief counseling
on engagement in behaviors to prevent T2DM and mediators of these behaviors.
Inclusion Criteria:
The investigators will recruit 315 non-diabetic Veterans receiving primary care at the Ann
Arbor VA Medical Center who meet the following inclusion criteria:
- willing to complete a HIPAA authorization form
- no HbA1c results in previous 12 months
- due for VA Primary Care appointment approximately 12 weeks of sending a recruitment
letter and who have a body-mass index (BMI) 30 kg/m2
- or BMI 25 kg/m2 with > 1 obesity-related condition such as:
- hypertension
- hyperlipidemia
- Hypoalphalipoproteinemia
- Coronary Artery Disease
- Peripheral Vascular Disease
- Hypertriglyceridemia
- past hemoglobin A1c (HbA1c) of 5.7 - 6.4
- past diagnosis of Impaired Fasting Glucose (IFG)
- or Impaired Glucose Tolerance (IGT)
- or Polycystic Ovary Syndrome (PCOS)
Exclusion Criteria:
- The investigators will exclude patients who are > 75 years of age
- are receiving chemotherapy for cancer, or have:
- dementia
- diabetes
- dementia
- New York Heart Association Class III or IV congestive heart failure
- pregnancy
- Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 4 Chronic
Obstructive Pulmonary Disease (COPD)
- end-stage renal disease (ESRD)
- cirrhosis
- or have been hospitalized or received rehab for stroke or myocardial infarction
within the past 6 months
We found this trial at
1
site
Click here to add this to my saved trials
